i3 Verticals Divests Healthcare RCM Business
Greg Daily, Chairman and CEO of i3 Verticals, stated, 'Several years ago we set off to build a platform to deliver fantastic revenue cycle management solutions for the healthcare industry. We are proud of what we built and continue to believe that this is an attractive market. However, we also recognize that scale is important in revenue cycle management, and our future is in providing enterprise software solutions in other markets. We found a great partner, and our healthcare management team will be well positioned to accomplish great things with Infinx.
'After the divestiture, we will be completely streamlined, focused on the Public Sector vertical, including the K-12 public education markets. We believe that focusing our efforts in this targeted area will maximize our growth potential and allow us to bring our customers the best possible service. We look forward to driving innovation and excellence in these sectors.'
Jaideep Tandon, Chairman and CEO of Infinx, stated, 'We're thrilled to welcome the i3 Verticals Healthcare RCM team and their customers into the Infinx family. Their deep experience supporting Academic Medical Centers, along with the strong and trusted relationships they've built over time, is a powerful complement to our mission. By combining their domain expertise with our AI-powered RCM Insights, patient access, and automation solutions, we look forward to working alongside them to deliver meaningful financial and clinical outcomes for healthcare providers nationwide.'
Advisors
Raymond James & Associates, Inc. served as financial advisors to i3 Verticals and Bass, Berry and Sims, PLC served as legal advisor to i3 Verticals.
Stinson LLP served as legal advisor to Infinx.
About i3 Verticals
The Company delivers seamless enterprise software to customers in strategic vertical markets. Building on its sophisticated and diverse platform of software and services solutions, the Company creates and acquires software products to serve the specific needs of public and private organizations in the Public Sector (including K-12 public education).
About Infinx
Founded in 2012, Infinx provides scalable, AI-driven solutions to optimize the financial lifecycle of healthcare providers across all functions of patient access and revenue cycle management. Its cloud-based software, powered by AI and automation, is leveraged by experienced consultants and billing specialists across the U.S., India, and the Philippines. Infinx helps 172,000 healthcare professionals across 4,000 facilities capture more revenue, stay ahead of changing regulations and payer guidelines, and focus on patient care.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, which involve risk and uncertainties.
You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as 'anticipate,' 'estimate,' 'expect,' 'project,' 'plan,' 'intend,' 'believe,' 'may,' 'will,' 'should,' 'could have,' 'exceed,' 'significantly,' 'likely' and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events.
These forward-looking statements are based on the Company's current beliefs, understandings and expectations. These forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond the Company's control, which could cause actual results to differ materially from those contemplated in these forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied include risks associated with the Company's ability to execute on its strategy and achieve its goals and other expectations after completion of these transactions and risks related to the ancillary agreements entered at the closing of these transactions, as well as the risks set forth in the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2024, filed with the Securities and Exchange Commission on November 25, 2024, the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended December 31, 2024, filed with the Securities and Exchange Commission on February 7, 2025, and the Company's other filings with the Securities and Exchange Commission.
Any forward-looking statement made by the Company in this press release speaks only as of the date of this press release, and the Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
Etoiles Capital Group Co., Ltd Announces Closing of Underwriters' Over-Allotment Option in Connection with Initial Public Offering
HONG KONG, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Etoiles Capital Group Co., Ltd (Nasdaq: EFTY), a Hong Kong-based financial services provider, today announced that it closed the sale of an additional 210,000 Class A ordinary shares of the Company, pursuant to the full exercise of the underwriters' over-allotment option granted in connection with the Company's initial public offering ('IPO', together with such over-allotment closing, the 'Offering'), at the IPO price of $4.00 per share, less underwriting discounts. As a result, the Company has raised aggregate gross proceeds of $6,440,000, including the previously announced IPO gross proceeds of $5,600,000, prior to deducting underwriting discounts and commissions and offering expenses payable by the Company. Proceeds from the Offering will be used for business expansion, technology infrastructure, strategic marketing, and general corporate purposes. The Offering was conducted on a firm commitment basis. Prime Number Capital, LLC acted as the representative underwriter and sole book- runner for the Offering. Loeb & Loeb LLP acted as the U.S. counsel to the Company, Ogier acted as the Cayman Islands counsel to the Company, and Ye & Associates, P.C. acted as the U.S. counsel to the underwriting syndicate in connection with the Offering. A registration statement on Form F-1 relating to the Offering was filed with the U.S. Securities and Exchange Commission ('SEC') (File Number: 333-287302) and was declared effective by the SEC on August 7, 2025. The Offering was made only by means of a prospectus, forming a part of the registration statement. A final prospectus relating to the Offering was filed with the SEC on August 7, 2025, which may be obtained from Prime Number Capital, LLC, 12 E 49 St, Floor 27, New York, NY 10017, Attention: Shenghui Yang by email at ecm@ or by calling +1(347) 329-1575. In addition, copies of the prospectus relating to the Offering may be obtained via the SEC's website at This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction. Forward-Looking StatementsCertain statements in this announcement are forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company's current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. Investors can identify these forward-looking statements by words or phrases such as 'approximates,' 'assesses,' 'believes,' 'hopes,' 'expects,' 'anticipates,' 'estimates,' 'projects,' 'intends,' 'plans,' 'will,' 'would,' 'should,' 'could,' 'may' or similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and other filings with the SEC. About Etoiles Capital Group Co., LtdEtoiles Capital Group Co., Ltd (Nasdaq: EFTY) is a Cayman Islands holding company operating through its Hong Kong subsidiary, Etoiles Consultancy Limited. The Company provides comprehensive financial advisory, capital markets services, and integrated solutions—including corporate financing, initial public offering consulting, and investor relations—to clients navigating global capital markets. ContactsIssuer InquiriesEtoiles Capital Group Co., LtdRoom 1109, 11/F, Tai Yau Building181 Johnston Road, Wanchai, Hong KongTel: +852 2398 8699 | Email: ir@ Underwriter InquiriesPrime Number Capital, LLC27F, 12E 49th Street, New York, NY 10017Tel: (347) 329-1575 | Email: info@
Yahoo
a few seconds ago
- Yahoo
Why CoreWeave Stock Is Plummeting Today
Key Points CoreWeave reported Q2 2025 financial results after the market closed yesterday. Investors had lofty expectations for the company's recent performance. Today's pullback provides a good opportunity for AI-focused investors to start a position. 10 stocks we like better than CoreWeave › Before the market opened today, CoreWeave (NASDAQ: CRWV) had ripped 30% higher since the start of August. Today, however, investors are sending the artificial intelligence (AI) stock in the other direction. AI investors are unhappy with the second-quarter 2025 financial results that the company released yesterday after the market closed and are clicking the sell button today. As of 9:45 a.m. ET, shares of CoreWeave were down 13.8%. Investors had sky-high expectations for this AI cloud stock After combing through CoreWeave's Q2 2025 financial results, investors would be hard-pressed to find areas in which the company stumbled. CoreWeave posted revenue of $1.21 billion, beating analyst expectations that it would report sales of $1.08 billion. With respect to profitability, CoreWeave reported adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of $753.2 million, a notable increase over the adjusted EBITDA of $249.8 million it reported during the same period last year, and $606.1 million in adjusted EBITDA it reported during Q1 2025. Another source of encouragement was the company's strong backlog growth. At the end of Q2 2025, CoreWeave had a $30.1 billion backlog, a 30.1% year-over-year increase. This impressive growth helped motivate management to upwardly revise 2025 guidance. Whereas CoreWeave had projected 2025 revenue of $4.9 billion to $5.1 billion initially, it now expects to report $5.15 billion to $5.35 billion on the top line. Does today's sell-off provide a solid buying opportunity? Although there was a lot to celebrate regarding CoreWeave's Q2 2025 performance, it wasn't enough to placate investors who had lofty expectations. Fortunately for those who had been sitting on the sidelines, today's pullback in CoreWeave stock provides a great opportunity to start -- or add to -- a position. It wouldn't be surprising if this pullback doesn't last and shares start to resume their upward trajectory in the very near future. Appetite for AI exposure remains robust, and CoreWeave's position as a leading AI hyperscaler has made CoreWeave stock highly desirable for AI-focused investors. Should you buy stock in CoreWeave right now? Before you buy stock in CoreWeave, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and CoreWeave wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 13, 2025 Scott Levine has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. Why CoreWeave Stock Is Plummeting Today was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
2 minutes ago
- Business Wire
Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Vyome Therapeutics, Inc., a clinical-stage healthcare company targeting immuno-inflammatory and rare diseases in the US and global markets with large market potential, today announced that The Nasdaq Stock Market has approved its listing upon completion of the Company's previously announced merger with ReShape Lifesciences (Nasdaq: RSLS), which is expected to take effect for marketplace purposes with the open of trading on Friday, August 15, 2025 under the name Vyome Holdings, Inc. and the trading symbol 'HIND.' 'Nasdaq's approval is right on track and now we are marching forward to ring the bell on our planned listing date this Friday. We look forward to welcoming RSLS shareholders and invite all others who wish to be part of our journey, which I promise will at all times be focused only on shareholder value. If you believe in the global healthcare market, in the opportunities to do business between the US and India, and in the value of a group of smart people driving real innovation across science and AI, you believe in Vyome,' said Krishna Gupta, Chairman of Vyome. 'Inflammation is one of the most impactful chronic conditions afflicting humanity today. There are a large number of inflammatory diseases, a market exceeding over $100B, and all connected to our immune system not functioning as it should. Vyome's existing, clinical stage assets – developed over years of work – are focused on major unmet indications in this immuno-inflammatory space,' said Shiladitya Sengupta, founder of Vyome and Associate Professor of Medicine at Harvard Medical School. In connection with the expected completion of the merger and Nasdaq requirements, ReShape's Board of Directors has declared a 1-for-4 reverse stock split of the company's common stock, which will also be effective for marketplace purposes upon the commencement of trading on August 15, 2025. At that time, each four shares of issued and outstanding common stock and equivalents will be converted into one share of common stock. The new CUSIP number for the company's common stock following the reverse stock split and merger will be 92943X104. The reverse split does not impact the post-merger ownership allocations between the ReShape and Vyome shareholders in the deal. About Vyome Vyome Therapeutics is building a healthcare platform spanning the US-India innovation corridor. Vyome's immediate focus is leveraging its clinical-stage assets to transform the lives of patients with immuno-inflammatory conditions. By applying groundbreaking science and its unique positioning across the US-India innovation corridor, Vyome seeks to deliver lasting value to shareholders in a hyper cost-efficient manner while upholding global standards of quality and safety. Based in Cambridge, MA, the company has announced its intent to be listed on the Nasdaq exchange under the ticker 'HIND' pursuant to a reverse merger with ReShape Lifesciences Inc. (Nasdaq: RSLS) on August 15, 2025. To learn more, please visit Forward-Looking Statements Certain statements contained in this document are "forward-looking statements." Examples of such statements include, but are not limited to, statements relating to the anticipated timing and completion of the proposed merger and reverse stock split and the combined company's listing on the Nasdaq Stock Market after closing of the proposed merger. ReShape and/or the combined company may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management's current expectations and involve risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, risks and uncertainties associated with the ability to consummate the proposed merger through the process being conducted by the parties. ReShape disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made.
